Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Bristol-Myers Squibb shells out billions for Mirati: 5 big deal reports

Published 10/09/2023, 07:26 AM
© Reuters.

Investing.com — Here is your Pro Recap of 5 head-turning deal dispatches you may have missed last week: deals at Bristol Myers Squibb/Mirati Therapeutics, Eli Lilly/Point Biopharma, Suncor Energy/TotalEnergies, deal talks at Exxon Mobil/Pioneer Natural Resources, and potential sale of EngageSmart.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

Bristol Myers Squibb acquires Mirati Therapeutics in a deal worth up to $5.8 billion

Bristol-Myers Squibb (NYSE:BMY) said Sunday that it has agreed to buy out Mirati Therapeutics (NASDAQ:MRTX) for $58.00 per share in cash, for a total equity value of $4.8 billion.

Mirati shareholders will also be granted a non-tradeable Contingent Value Right (CVR) for each Mirati share held, with the potential to be valued at $12 per share in cash, presenting an extra $1B in potential value.

Earlier last week, Reuters reported that French pharmaceutical giant Sanofi (NASDAQ:SNY) is exploring a potential acquisition of Mirati Therapeutics, which led to a 45% share surge on Thursday.

InvestingPro | Unlock the Market's

ExxonMobil in talks to acquire Pioneer Natural Resources for $60B

Pioneer Natural Resources (NYSE:PXD) soared 10% Friday on reports of ongoing negotiations between Exxon Mobil (NYSE:XOM) and the shale driller.

According to sources cited by the Wall Street Journal, this potential blockbuster deal could be valued at around $60B and may be finalized in the coming days, marking one of the oil group's largest acquisitions in more than two decades.

Pioneer shares were recently up another 1.7% in premarket trading Monday. Exxon shares were climbing 2.5%.

Point Biopharma to be acquired by Eli Lilly for $1.4B

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

POINT Biopharma Global (NASDAQ:PNT) shares surged by more than 85% last Tuesday after Eli Lilly (NYSE:LLY) said it had agreed to buy the cancer biotech for around $1.4 billion. Under the terms of the deal, Lilly is offering $12.50 per Point Biopharma share held. Both Point and Lilly expect the deal to close by the end of the year.

Eli Lilly shares closed the week with more than a 5% gain.

Suncor buys TotalEnergies Canada

Suncor Energy (NYSE:SU) said it picked up TotalEnergies' (EPA:TTEF) Canada operations - TotalEnergies EP Canada Ltd - which holds a 31.23% working interest in the Fort Hills oil sands mining project, for C$1.468 billion.

Upon closing of the transaction, Suncor will own 100% of Fort Hills, which along with its 100% ownership of Firebag and MacKay River in-situ assets, enhances Suncor's access to long-life, physically-integrated bitumen supply, maximizing the utilization of its wholly-owned Base Plant upgraders post the end of the Base Mine life.

General Atlantic mulls sale of EngageSmart

General Atlantic LLC, a private equity firm, is reportedly considering the sale of EngageSmart (NYSE:ESMT), per Reuters. Investment banks Goldman Sachs Group and Evercore are working with EngageSmart on a sale process, which is in its early stages.

According to the report, no definitive deal has been confirmed, and General Atlantic, which holds a 54% stake in EngageSmart, may opt for a gradual sell-down of its stake on the stock market instead.

EngageSmart shares closed the week with more than a 15% gain.

***

Get a leg up on the market: Always be the first to know with InvestingPro.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

InvestingPro | Be The First To Know

Latest comments

10
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.